SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Jun 5, 2018
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: June 5, 2018 · CIK: 0001213037 · Accession: 0001193125-18-184602
AI Filing Summary & Sentiment
File numbers found in text: 333-224808
Letter
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92921
June 5, 2018
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dorrie Yale
Re: Trovagene Inc.
Registration Statement on Form S-1, as amended
File No. 333-224808
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time, on Thursday, June 7, 2018, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
Thank you,
TROVAGENE, INC.
By:
/s/ William Welch
Name:
William Welch
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP Trovagene, Inc. 11055 Flintkote Avenue San Diego, CA 92921 June 5, 2018 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Re: Trovagene Inc. Registration Statement on Form S-1, as amended File No. 333-224808 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time, on Thursday, June 7, 2018, or as soon thereafter as possible. Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. Thank you, TROVAGENE, INC. By: /s/ William Welch Name: William Welch Title: Chief Executive Officer